Endocrine Society Learning Center

Diabetes Diagnosis & Management 2011

ACCREDITATION STATEMENT
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this enduring material for a maximum of 7.75 AMA PRA Category 1 Credit(s)�. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the suapervision of The Endocrine Society's Special Programs Committee (SPC). The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations.

DISCLAIMER
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society.

LEARNING OBJECTIVES
Upon completion

Evaluate clinical practice guidelines
Compare and critique current glycemia
Recognize patient barriers to medication
Define medically significant weight loss and
Select appropriate medical therapy options for
Effectively describe the appropriate use of
Choose the best therapeutic options for
Identify blood pressure treatment targets and
Appropriately manage insulin dosing during
Recognize the causes and risk of recurrent
Recognize the adverse outcomes associated with
Recognize the progression of beta-cell
Design insulin treatment programs that address
Initiate effective treatment programs that
Manage physiologic insulin replacement
Explain the indications and limitations of
Utilize continuous glucose monitoring data to
Teach patients how to make the best use of
Recognize and treat hyperglycemia as an
Employ appropriate techniques to achieve and
Describe the mechanisms of action of new

TARGET AUDIENCE
This program should be of of this educational activity, learners will be able to: on diabetes and management of comorbidities and predict how these will evolve in light of new data and clinical experience algorithms and discuss the place for new therapies within them adherence and suggest strategies to overcome them its impact on glycemic parameters the co-management of diabetes and obesity incretin mimetics and DPP-4 inhibitors in diabetes treatment managing dyslipidemia in patients with T2DM preferred pharmacologic treatment options for patients with diabetes exercise hypoglycemia and hypoglycemia unawareness hypoglycemia and ways to prevent hypoglycemic events with particular attention to selection of medical therapies and matching the anti-hyperglycemic regimen to nutritional intake dysfunction in the pathophysiology of T2DM the current stage of insulin resistance integrate multiple therapies, including oral medications and insulin regimens programs based on the individual's needs available continuous glucose monitors make clinical decisions their continuous glucose monitors to achieve tight glycemic control independent risk factor for predicting cardiovascular events and mortality maintain normoglycemia in in-patients classes of therapies including SGLT2 and PPARα/γ ligands substantial interest to: endocrinologists and endocrine fellows, pediatric endocrinologists and pediatric endocrine fellows, endocrine physician's assistants and internal medicine physicians who treat diabetes, geriatricians, nurses, and other healthcare professionals who treat patients with diabetes.

DISCLOSURE POLICY
The faculty, committee members, and staff involved in planning this CME activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consultant fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
Lawrence Blonde, MD, FACP has received consultant fees from Amylin Pharmaceuticals, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Halozyme, Johnson & Johnson, Mannkind Corporation, Merck & Co., Novo Nordisk, Orexigen Therapeutics, Roche, sanofi-aventis, Santarus, and VeroScience; speaker fees from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Daiichi sankyo, Merck & Co., Novo Nordisk, Santarus, and Vero Science; research grant support from Boehringer Ingelheim Pharmaceuticals, Eli Lily and Company, Johnson & Johnson, Novo Nordisk, Roche, and sanofi-aventis; and owns stock in Amylin Pharmaceuticals and Pfizer.

Bruce Bode, MD has received consultant fees from Dexcom, research grant support from Medtronic, and speaker honoraria from Dexcom.

Kenneth R. Feingold, MD has received consultant fees from Genzyme and speaker honoraria from Abbott Laboratories, Amylin Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Merck & Co., and Takeda Pharmaceutical Company.

Irl Hirsch, MD has received consultant fees from Abbott Laboratories, Bayer, Johnson & Johnson, and Roche and research grant support from Halozyme Therapeutics, MannKind Corporation, and Novo Nordisk.

John (Jack) L. Leahy, MD has received consultant fees from Merck & Co. and Novo Nordisk; research grant support from Takeda Pharmaceutical Company; and speaker honoraria from sanofi-aventis U.S.

Holly R. Wyatt, MD has received author royalties from UpToDate; consultant fees from Arena Pharmaceuticals, Wellspring Academies, and Allergan; holds ownership interest in Active Planet; and has received research grant support from Amylin Pharmaceuticals and Novo Nordisk.

Carol Wysham, MD has received consultant fees from Amylin Pharmaceuticals and Eli Lilly & Co. and speaker fees from Merck & Co., Novo Nordisk, and sanofi-aventis U.S.

The following faculty reported no relevant financial relationships:
Clifford J. Bailey, PhD, FRCP; Charlotte M. Boney, MD; Robert M. Carey, MD; Anthony McCall, MD, PhD; Donald C. Simonson, MD, MPH, ScD; Greet Van den Berghe, MD, PhD; and Robert A. Vigersky, MD

The following Special Programs Committee members who planned and/or reviewed content for this activity reported relevant financial relationships:
Kieren J. Mather, MD has received consultant fees from Santarus and VeroScience and speaker honoraria from Merck & Co., Santarus, and VeroScience.

The following faculty reported no relevant financial relationships:
Clifford J. Bailey, PhD, FRCP; Charlotte M. Boney, MD; Robert M. Carey, MD; Anthony McCall, MD, PhD; Donald C. Simonson, MD, MPH, ScD; Greet Van den Berghe, MD, PhD; and Robert A. Vigersky, MD

The following Special Programs Committee members who planned and/or reviewed content for this activity reported relevant financial relationships:
Kieren J. Mather, MD has received consultant fees from Santarus and VeroScience and speaker honoraria from Merck & Co., Santarus, and VeroScience.

POLICY ON UNLABELED/OFF-LABEL USAGE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY & CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grant(s) from Amylin Pharmaceuticals, Inc. and Lilly USA, LLC; Daiichi Sankyo, Inc.; Lilly USA, LLC; and Merck & Co., Inc.

METHOD OF PARTICIPATION
This enduring material is presented in an online/computer-based format. System requirements include:

For Windows, Firefox 1.5 or Internet Explorer 7.0 with Flash 8 or better installed.
For Macintosh OS X, Safari 2.0 or Firefox 1.5 with Flash 8 or better installed.

To receive a maximum of 7.75 AMA PRA Category 1 Credits�, participants should:

Select a session and listen to the audio and/or view the slides.

Complete the evaluation provided at the end of the session and click on "submit" to add the session to the learner's transcript. The transcript will appear and the learner will have the option of printing a CME certificate then or at a later time, after viewing multiple sessions.

Select additional sessions and proceed as directed above, to accumulate credits for participating in multiple sessions.

Credits awarded correspond to the length of time for each session, which varies from 0.5 to 1.0 hours

The estimated time to complete this activity, including review of material, is 7.75 hours.

Last Review Date: June, 2011
Activity Release/Expiration Date: June 2011 through June 2012

For technical assistance or information, please contact call 972-910-6899 (9:00 AM to 5:00 PM EST) or E-mail: multiviewMediaSupport@multiview.com.

For questions regarding CME content or obtaining CME credit, please contact The Endocrine Society at 301.941.0200 or education@endo-society.org.

I have read the CME guidelines outlined.